Rapid, efficient purification of HSV-specific T-lymphocytes...

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S006120

Reexamination Certificate

active

07431934

ABSTRACT:
Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

REFERENCES:
patent: 4859587 (1989-08-01), Roizman
patent: 5538724 (1996-07-01), Butcher
patent: 6375952 (2002-04-01), Koelle
patent: 6413518 (2002-07-01), Koelle
patent: 6814969 (2004-11-01), Koelle
patent: 6855317 (2005-02-01), Koelle
patent: 6962709 (2005-11-01), Koelle
patent: 7037509 (2006-05-01), Koelle
patent: 2002/0090610 (2002-07-01), Hosken et al.
patent: WO 95/06055 (1995-05-01), None
patent: WO 98/20016 (1998-05-01), None
patent: WO 01/23414 (2001-04-01), None
De Plaen, E., “Cloning of Genes Coding for Antigens Recognized by Cytolytic T Lymphocytes,” Immunology Methods Manual, 1997, 692-718.
Dolan, A., The Genome Sequence of Herpes Simplex Virus Type 2, Journal of Virology, 1998, 72(3):2010-2021.
Fuhlbrigge, Robert C. et al., “Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells”, Nature, Oct. 30, 1997, vol. 389, pp. 978-981.
Khan, Naeem et al., “Comparative Analysis of CD8+ T Cell Responses against Human Cytomegalovirus Proteins pp65 and Immediate Early 1 Shows Similarities in Precursor Frequency, Oligoclonality, and Phenotype”, The Journal of Infectious Diseases, Mar. 2002, vol. 185, pp. 1025-1034.
Koelle, D.M., “Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells . . . ” Jnl. of Virology, 1998, 72(9):7476-7483.
Koelle, D.M., “The Roles of T Lymphocytes in Host Responses to Herpes Simplex Virus,” Herpes, 1995, 2:83-88.
Koelle, D.M., “Clearance of HSV-2 from Recurrent Genital Lesions Correlates with Infiltration of HSV-Specific Cytotoxic T Lymphoctyes,” The Journal of Clinical Investigation, 1998, 101(7):1500-1508.
Koelle, D.M., “Preferential Presentation of Herpes Simplex Virus T-Cell Antigen by HLA DQA1*0501/DQB1*0201 in Comparison to HLA DQA1*0201/DQB1*0201,” Human Immunology, 1997, 53(2):195-205.
Koelle, D.M., “Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions,” The Journal of Infectious Diseases, 1994, 169:956-61.
Koelle, D.M.., “Antigenic Specificities of Human CD+T-Cell Clones Recovered from Recurrent Genital Herpes Simples Virus Type 2 Lesions,” Journal of Virology, 1994, 68(5):2803-2810.
Kwok, W.W., “Peptide Binding Affinity and pH Variation Establish Functional Thresholds for Activation of HLA-DQ-Restricted T Cell Recognition,” Human Immunology, 1999, 60(7):619-626.
Marshall, Natalie A., “Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation”, Immunology, Oct. 15, 2000, Blood, vol. 96, No. 8, pp. 2814-2821.
Paoletti, “Applications of Pox Virus Vectors to Vaccination: An Update,” Proceedings of the National Academy of Science USA, Oct. 1996, 93:11349-11353.
Pober, Jordan S. et al., “Human Endothelial Cell Presentation of Antigen and the Homing of Memory/Effector T Cells to Skin”, Annals New York Academy of Sciences, 2001, vol. 941, pp. 12-25.
Posavad, C.M., “High Frequency of CD8+Cytotoxic T-Lymphoctye Precursors Specific for Herpes Simplex Viruses in Persons with Genital Herpes,” Journal of Virology, 1996, 70(11):8165-8168.
Reichstetter, S., “MCH-Peptide Ligand Interactions Establish a Functional Threshold for Antigen-Specific T Cell Recognition,” Human Immunology, 1999, 60(7):608-618.
Roizman, B., “Herpes Simplex Viruses and Their Replication”, Fundamental Virology, 2ndEdition, ed. Fields et al, Raven Press, 1991, New York, pp. 849-895.
Stanberry, “Glycoprotein-D-Adjuvant Vaccine to Prevent Genital Herpes,” N. Engl. J. Med., 2002, 347(21):1652-1661.
Stanberry, Lawrence R., “Prospects for Control of Herpes Simplex Virus Disease through Immunization”, Clinical Infectious Diseases, Mar. 2000, vol. 30, pp. 549-566.
Tigges, M.A., “Human CD8+Herpes Simplex Virus-Specific Cytotoxic T-Lymphocyte Clones Recognize Diverse Virion Protein Antigens,” Journal of Virology, 1992, 66(3):1622-1634.
Williams, “Characterization of a Herpes Simplex Virus Type 2 Deoxyuridine . . . ” Virology, 1987, 156:282-292.
Williams, “Deoxyuridine Triphosphate Nucleotidohydrolase Induced by Herpes Simplex Virus Type 1,” Jnl. of Biological Chemistry, 1984, 259(16): 10080-10084.
Homey, B., “CCL27-CCRIO Interactions Regulate T Cell-mediated Skin Inflammation”, Nature Medicine, Feb. 1992, 8(2).
Koelle, D.M., “CD8 CTL from Genital Herpes Simplex Lesions; Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells”, Journal of Immunology, Mar. 2001, 166(6):4049-4058.
Koelle, D.M., “Expression of Cutaneous Lymphocyte-associated Antigen by CD8(+) T Cells Specific for a Skin-trophic Virus”, The Journal of Clinical Investigation, Aug. 2002, 110(4):537-548.
Nozawa, Naoki, “Identification and Characterization of the UL7 Gene Product of Herpes Simplex Virus Type 2”, Virus Genes, Jun. 2002, 24(3):257-266.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Rapid, efficient purification of HSV-specific T-lymphocytes... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rapid, efficient purification of HSV-specific T-lymphocytes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid, efficient purification of HSV-specific T-lymphocytes... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3995489

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.